Report Categories Report Categories

Report Categories

industry Category

All

Total: 2 records, 1 pages

Global Pneumococcal 13-valent Conjugate Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 28 Oct 2024

date Pharma & Healthcare

new_biaoQian Pneumococcal 13-valent Conjugate Vaccine

The Pneumococcal 13-valent Conjugate Vaccine (PCV13) is a vaccine designed to protect against infections caused by Streptococcus pneumoniae bacteria, commonly known as pneumococcus. It targets 13 specific strains (or serotypes) of the bacteria, which are responsible for severe illnesses such as pneumonia, meningitis, and sepsis. By preventing these infections, PCV13 is particularly important in protecting young children, and people with weakened immune systems.

USD3480.00

Add To Cart

Add To Cart

Global Pneumococcal 13-valent Conjugate Vaccine Supply, Demand and Key Producers, 2024-2030

date 28 Oct 2024

date Pharma & Healthcare

new_biaoQian Pneumococcal 13-valent Conjugate Vaccine

The Pneumococcal 13-valent Conjugate Vaccine (PCV13) is a vaccine designed to protect against infections caused by Streptococcus pneumoniae bacteria, commonly known as pneumococcus. It targets 13 specific strains (or serotypes) of the bacteria, which are responsible for severe illnesses such as pneumonia, meningitis, and sepsis. By preventing these infections, PCV13 is particularly important in protecting young children, and people with weakened immune systems.

USD4480.00

Add To Cart

Add To Cart

industry 28 Oct 2024

industry Pharma & Healthcare

new_biaoQian Pneumococcal 13-valent Conjugate Vaccine

The Pneumococcal 13-valent Conjugate Vaccine (PCV13) is a vaccine designed to protect against infections caused by Streptococcus pneumoniae bacteria, commonly known as pneumococcus. It targets 13 specific strains (or serotypes) of the bacteria, which are responsible for severe illnesses such as pneumonia, meningitis, and sepsis. By preventing these infections, PCV13 is particularly important in protecting young children, and people with weakened immune systems.

USD3480.00

addToCart

Add To Cart

industry 28 Oct 2024

industry Pharma & Healthcare

new_biaoQian Pneumococcal 13-valent Conjugate Vaccine

The Pneumococcal 13-valent Conjugate Vaccine (PCV13) is a vaccine designed to protect against infections caused by Streptococcus pneumoniae bacteria, commonly known as pneumococcus. It targets 13 specific strains (or serotypes) of the bacteria, which are responsible for severe illnesses such as pneumonia, meningitis, and sepsis. By preventing these infections, PCV13 is particularly important in protecting young children, and people with weakened immune systems.

USD4480.00

addToCart

Add To Cart